Trials / Completed
CompletedNCT00092742
Investigational Drug Versus an Approved Drug in Patients With Rheumatoid Arthritis (0663-072)
A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib 90 mg q.d. vs. Diclofenac Sodium 75 mg b.i.d. in Patients With Rheumatoid Arthritis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 4,086 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the long-term safety of an investigational drug versus an approved drug for the relief of pain in patients with rheumatoid arthritis.
Detailed description
The duration of treatment is 12 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK0663, etoricoxib | |
| DRUG | Comparator: Diclofenac sodium |
Timeline
- Start date
- 2003-02-01
- Primary completion
- 2005-12-01
- Completion
- 2005-12-01
- First posted
- 2004-09-28
- Last updated
- 2022-02-16
Source: ClinicalTrials.gov record NCT00092742. Inclusion in this directory is not an endorsement.